Status: Recruiting
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Climb Bio, Inc.Updated: Mar 27, 2026Locations: 20
Eligibility criteria
Aged 18 years at the time of consent. [+2]
CD19+ B cell count < 80 cells/µL at Screening, or < 40 cells/µL if B-cell deplet... [+8]